ReviewAmerican journal of translational research2026
PSMA PET/CT improves precision diagnosis, treatment, and clinical decision-making in prostate cancer.
Review in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is one of the most prevalent malignancies in males worldwide. Its diagnosis and treatment have long faced challenges, including inaccurate disease staging, difficulty in localizing recurrence sites, and a lack of evidence for individualized decision-making. Recently, prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) technology has emerged as a major breakthrough in addressing these limitations. This review systematically summarizes the technical principles and clinical applications of PSMA PET/CT, and evaluates its impact on diagnostic and therapeutic paradigms of prostate cancer, including its role in precision staging for high-risk patients at initial diagnosis, early localization of biochemical recurrence sites, target delineation for radical therapy, screening of oligometastatic patients for targeted metastatic treatment, as well as its central function in integrated diagnosis and treatment. In addition, this review discusses current limitations of the technology, including inconsistent interpretation standards and controversies over health economics. Future perspectives are also outlined, focusing on the development of novel tracers, the integration of artificial intelligence, and multidisciplinary collaboration. Through the integration of a large amount of clinical research data, this review aims to demonstrate the transformative value of PSMA PET/CT in the diagnosis and treatment of prostate cancer, and to provide evidence-based support for clinical practice and future guideline updates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.